Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.

ABSTRACT:

Introduction

Infections are a leading cause of morbidity and mortality in patients with multiple myeloma (MM).

Methods

To examine the effects of modern second-generation novel agent therapy on immune cell subsets, in particular CD4+-T-cells, and infectious complications in patients with relapsed/refractory MM (RRMM), we conducted a prospective cohort study in 112 RRMM patients.

Results

Substantially decreased CD4+-T-cells <200/µl before initiation of relapse therapy were detected in 27.7% of patients and were associated with a higher number of previous lines of therapy. Relapse therapy with carfilzomib or pomalidomide showed a significant further decrease of CD4+-T-cells. All novel agents led to a significant decrease of B-cell counts. Overall, infections were frequen

SUBMITTER: John L 

PROVIDER: S-EPMC10160457 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature